Cost-Benefit Analysis of Tafenoquine for Radical Cure of Plasmodium vivax Malaria in Korea
Open Access
- 1 January 2022
- journal article
- research article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (27) , e212
Abstract
Suh J, et al. J Korean Med Sci. 2022 Jun;37(27):e212. https://doi.org/10.3346/jkms.2022.37.e212Keywords
Funding Information
- National Research Foundation of Korea (NRF-2020R1A2C1A01010775)
- Government-wide R&D Fund (GFID-HG20C0003)
This publication has 41 references indexed in Scilit:
- Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquineCochrane Database of Systematic Reviews, 2013
- Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax MalariaNew England Journal of Medicine, 2013
- The metabolism of primaquine to its active metabolite is dependent on CYP 2D6Malaria Journal, 2013
- Clinical Characteristics of Vivax Malaria and Analysis of Recurred PatientsInfection & Chemotherapy, 2013
- G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based MapPLOS Medicine, 2012
- Primaquine radical cure of Plasmodium vivax: a critical review of the literatureMalaria Journal, 2012
- CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquineMalaria Journal, 2012
- Relapse2012
- Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon RegionMalaria Journal, 2011
- The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysisBlood Cells, Molecules, and Diseases, 2009